Chronic migraine affects daily life in ways that go far beyond pain. People with the condition experience headaches on at least 15 days each month, often with nausea, light sensitivity and difficulty working or socialising.
Preventive treatments exist, but many offer only modest relief or cause side effects that make them hard to continue.
New evidence now suggests that a newer group of migraine medicines may offer more reliable benefits with fewer problems than older options.
What we already know about migraine prevention
Preventive treatment aims to reduce how often migraines occur, rather than stopping individual attacks once they begin.
Traditional preventive medicines include drugs originally developed for epilepsy, high blood pressure or mood disorders, such as topiramate, propranolol and valproate.
While these medicines can help some people, many stop taking them because of side effects such as fatigue, weight changes or problems with concentration. Botulinum toxin injections, commonly known as Botox, are also used for chronic migraine, but their benefit varies between individuals.
What the new research examined
In a large systematic review published in Annals of Internal Medicine, researchers analysed 43 clinical trials involving adults with chronic migraine. All the studies were conducted in people, not animals or laboratory models.
The team compared several preventive treatments, focusing on how well they reduced the number of monthly migraine days and how well people tolerated them.
The main findings in plain language
The strongest and most consistent evidence supported medicines that target a protein called calcitonin gene‑related peptide, or CGRP. On average, these drugs reduced the number of migraine days by about two per month compared with placebo.
Importantly, people taking CGRP‑targeted treatments were less likely to stop treatment because of side effects than those using older medicines.
Examples of CGRP‑targeted therapies include eptinezumab, sold as Vyepti, and atogepant, sold as Qulipta. These medicines are already in clinical use in several countries.
How CGRP‑targeted treatments work
CGRP is a naturally occurring protein in the brain and nervous system. During a migraine attack, CGRP levels rise, contributing to pain signalling and inflammation around nerves and blood vessels.
CGRP‑targeted medicines work by blocking this process. Some bind directly to the CGRP protein, while others block its receptor, preventing CGRP from triggering pain pathways. By interrupting this chain of events, the medicines reduce the likelihood of migraines developing in the first place.
These treatments are available in different forms, including injections, intravenous infusions, tablets and a nasal spray.
How do older treatments compare?
The review found that botulinum toxin injections may provide some benefit, but the evidence was less certain. People receiving Botox were also more likely to experience side effects, which contributed to higher drop‑out rates in trials.
For older preventive medicines such as topiramate, valproate and propranolol, the evidence was weaker and more inconsistent. In many studies, benefits were modest and balanced by tolerability problems.
How strong is the evidence?
This review brings together a large number of clinical trials, which strengthens confidence in its overall conclusions. However, the authors note important limitations.
Many studies of CGRP‑targeted therapies were funded by pharmaceutical companies, and long‑term data remain limited. Most trials followed participants for months rather than years, leaving questions about sustained effectiveness and safety over time.
The researchers also stress that individual responses vary. A treatment that works well for one person may offer little benefit to another.
What this means for patients
For people with chronic migraine, the findings suggest that CGRP‑targeted therapies are currently among the most effective preventive options with the best balance between benefit and side effects.
However, this does not mean they are the right choice for everyone. Cost, access, method of delivery and other health conditions all play a role in treatment decisions. Current medical advice remains unchanged, treatment should be chosen through discussion between patients and their healthcare providers.
Costs, access and practical considerations
CGRP‑targeted medicines are generally more expensive than older drugs, and access may depend on insurance coverage or national health policies. In some healthcare systems, patients may need to try other preventive treatments first before qualifying for CGRP‑based therapies.
Botulinum toxin and older oral medicines still have a role, particularly for people who respond well to them or cannot use newer drugs.
What remains uncertain
The researchers call for more independent studies, especially those that follow patients over several years. Key unanswered questions include how well people continue treatment long term, whether benefits remain stable, and how these medicines compare directly with each other.
This review adds to growing evidence that targeting CGRP represents a meaningful step forward in migraine prevention. While no treatment offers a cure, clearer data on what works best can help guide more informed and personalised care.
For a condition that has long been frustrating to treat, the findings point to progress grounded in careful clinical research rather than hype.
The post New Migraine Medicines Show Clearer Benefit in Long‑Term Headaches, Major Review Finds first appeared on PP Health Malaysia.
